Clinigen Group PLC Company Profile (LON:CLIN)

About Clinigen Group PLC (LON:CLIN)

Clinigen Group PLC logoClinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:CLIN
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £1.01 billion
  • Outstanding Shares: 114,900,000
Average Prices:
  • 50 Day Moving Avg: GBX 841.89
  • 200 Day Moving Avg: GBX 795.79
  • 52 Week Range: GBX 492.75 - GBX 890
P/E:
  • Trailing P/E Ratio: 70.31683
  • P/E Growth: 0.00000
Sales & Book Value:
  • Annual Revenue: £315.2 million
  • Price / Sales: 3.20
  • Book Value: GBX 2.08 per share
  • Price / Book: 4.23
Profitability:
  • EBIDTA: £59.8 million
Misc:
  • Average Volume: 362,874 shs.
 

Frequently Asked Questions for Clinigen Group PLC (LON:CLIN)

What is Clinigen Group PLC's stock symbol?

Clinigen Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How often does Clinigen Group PLC pay dividends? What is the dividend yield for Clinigen Group PLC?

Clinigen Group PLC announced a dividend on Wednesday, March 15th. Investors of record on Thursday, March 23rd will be paid a dividend of GBX 1.60 per share on Thursday, April 13th. This represents a dividend yield of 0.2%. The ex-dividend date is Thursday, March 23rd. The official announcement can be accessed at this link. View Clinigen Group PLC's Dividend History.

Where is Clinigen Group PLC's stock going? Where will Clinigen Group PLC's stock price be in 2017?

4 brokerages have issued twelve-month price targets for Clinigen Group PLC's stock. Their predictions range from GBX 895 to GBX 1,015. On average, they anticipate Clinigen Group PLC's stock price to reach GBX 957.75 in the next twelve months. View Analyst Ratings for Clinigen Group PLC.

Who are some of Clinigen Group PLC's key competitors?

Who are Clinigen Group PLC's key executives?

Clinigen Group PLC's management team includes the folowing people:

  • Shaun Edward Chilton, Chief Executive Officer, Director

How do I buy Clinigen Group PLC stock?

Shares of Clinigen Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group PLC's stock price today?

One share of Clinigen Group PLC stock can currently be purchased for approximately GBX 879.


MarketBeat Community Rating for Clinigen Group PLC (LON CLIN)
Community Ranking:  4.7 out of 5 (   )
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  12 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Clinigen Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clinigen Group PLC (LON:CLIN) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 957.75

Analysts' Ratings History for Clinigen Group PLC (LON:CLIN)
Show:
DateFirmActionRatingPrice TargetDetails
5/22/2017Numis Securities LtdReiterated RatingBuyGBX 951View Rating Details
5/22/2017Stifel NicolausReiterated RatingBuyGBX 970View Rating Details
4/25/2017Peel HuntReiterated RatingBuyView Rating Details
4/13/2017N+1 SingerReiterated RatingBuyGBX 895View Rating Details
1/20/2016Royal Bank of CanadaLower Price TargetOutperformGBX 770 -> GBX 750View Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Clinigen Group PLC (LON:CLIN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Clinigen Group PLC (LON:CLIN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History by Quarter for Clinigen Group PLC (LON:CLIN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/15/2017GBX 1.600.2%3/23/20173/23/20174/13/2017
9/28/2016GBX 2.700.38%11/3/201611/3/201611/25/2016
3/2/2016GBX 1.300.2%3/17/20163/17/20164/8/2016
9/22/2015GBX 2.300.32%10/15/201510/15/201511/6/2015
9/24/2014GBX 2.100.46%10/16/201410/16/201411/7/2014
2/26/2014GBX 10.19%3/5/20143/5/20143/28/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Clinigen Group PLC (LON:CLIN)
Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2016John BaconInsiderSell200,000GBX 717£1,434,000
10/18/2016Shaun Edward ChiltonInsiderSell97,246GBX 750£729,345
5/16/2016Abell,MartinInsiderBuy11,296GBX 518£58,513.28
10/7/2015Edward Chilton,ShaunInsiderSell412,778GBX 685£2,827,529.30
6/3/2015John HartupInsiderSell23,934GBX 644£154,134.96
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Clinigen Group PLC (LON:CLIN)
Latest Headlines for Clinigen Group PLC (LON:CLIN)
Source:
DateHeadline
morningstar.co.uk logoClinigen Wins Support To Change Cardioxane Information In Europe
www.morningstar.co.uk - May 23 at 12:46 PM
americanbankingnews.com logoStifel Nicolaus Reiterates "Buy" Rating for Clinigen Group PLC (CLIN)
www.americanbankingnews.com - May 22 at 5:02 PM
americanbankingnews.com logoClinigen Group PLC's (CLIN) Buy Rating Reiterated at Numis Securities Ltd
www.americanbankingnews.com - May 22 at 4:28 PM
nasdaq.com logoTESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent ... - Nasdaq
www.nasdaq.com - May 11 at 10:01 PM
morningstar.co.uk logoClinigen Launches Managed Access Programme For Niraparib In Europe
www.morningstar.co.uk - May 11 at 4:59 PM
finance.yahoo.com logoTESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
finance.yahoo.com - May 11 at 2:36 AM
finanznachrichten.de logoEQS-News: European Mediscience Awards 2017 Shortlist announced
www.finanznachrichten.de - May 10 at 4:33 PM
finance.yahoo.com logoClinigen Group Plc – Value Analysis (LONDON:CLIN) : April 26, 2017
finance.yahoo.com - April 26 at 5:03 PM
globenewswire.com logoClinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell ... - GlobeNewswire (press release)
globenewswire.com - April 25 at 4:10 PM
finance.yahoo.com logoClinigen Group Plc breached its 50 day moving average in a Bullish Manner : CLIN-GB : April 25, 2017
finance.yahoo.com - April 25 at 12:13 PM
americanbankingnews.com logoPeel Hunt Reaffirms "Buy" Rating for Clinigen Group PLC (CLIN)
www.americanbankingnews.com - April 25 at 7:07 AM
finance.yahoo.com logoClinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)
finance.yahoo.com - April 24 at 4:15 PM
americanbankingnews.com logoN+1 Singer Reiterates Buy Rating for Clinigen Group PLC (CLIN)
www.americanbankingnews.com - April 13 at 2:42 PM
americanbankingnews.com logoClinigen Group PLC's (CLIN) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - April 8 at 6:08 PM
finance.yahoo.com logoClinigen Group Plc : CLIN-GB: Dividend Analysis : March 24th, 2017 (record date) : By the numbers : April 4, 2017
finance.yahoo.com - April 7 at 9:00 AM
americanbankingnews.com logoClinigen Group PLC (CLIN) Upgraded to Buy at Numis Securities Ltd
www.americanbankingnews.com - April 4 at 1:18 PM
businesswire.com logoClinigen Group plc: Strong H1 Performance with Adjusted EPS up 31%* - Business Wire (press release)
www.businesswire.com - March 16 at 5:39 PM
biz.yahoo.com logoHalf Year 2017 Clinigen Group PLC Earnings Release - Before Market Open
biz.yahoo.com - March 15 at 4:43 PM
uk.finance.yahoo.com logoClinigen Group plc: Strong H1 Performance with Adjusted EPS up 31%*
uk.finance.yahoo.com - March 15 at 6:41 AM
americanbankingnews.com logoClinigen Group PLC (CLIN) Earns Buy Rating from Numis Securities Ltd
www.americanbankingnews.com - March 10 at 7:37 PM
morningstar.co.uk logoClinigen Gets Approval To Launch Perampanel In South Africa
www.morningstar.co.uk - March 10 at 9:17 AM
nasdaq.com logoTesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer
www.nasdaq.com - January 17 at 9:00 AM
morningstar.co.uk logoClinigen Group Gives Exclusive US Licence For Totect To Cumberland
www.morningstar.co.uk - January 10 at 3:29 AM
finance.yahoo.com logoCumberland Pharmaceuticals and Clinigen Enter Exclusive U.S. Commercialization Agreement For Totect®
finance.yahoo.com - January 9 at 5:28 PM
finance.yahoo.com logoWasatch Invests in 7 New Holdings
finance.yahoo.com - December 12 at 9:39 PM

Social

Social activity is not available for this stock.

Chart

Clinigen Group PLC (CLIN) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff